Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Life (Basel, Switzerland)·2026

Same author

Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Liver international : official journal of the International Association for the Study of the Liver·2026

Same author

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Expert opinion on investigational drugs·2025

Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025

Same author

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Expert review of gastroenterology & hepatology·2025

Same author

Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world.

JHEP reports : innovation in hepatology·2025

Search research articles

Related Experiment Videos

Liver disorders in the elderly.

Annarosa Floreani¹

¹Dept. of Surgical and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, Padua, Italy.

Best Practice & Research. Clinical Gastroenterology

|November 28, 2009

Summary

This summary is machine-generated.

The aging population will increase liver disease prevalence, particularly in older adults. Management of conditions like chronic hepatitis C and autoimmune hepatitis requires tailored approaches in the elderly.

Related Experiment Videos

Area of Science:

Hepatology
Geriatric Medicine
Internal Medicine

Background:

The global population is aging, leading to a higher prevalence of liver diseases in elderly individuals.
Emerging liver conditions like non-alcoholic steatohepatitis and new treatments are of significant interest to hepatologists.
Certain liver diseases, including chronic hepatitis C and hepatocellular carcinoma, are more common in older adults.

Purpose of the Study:

To review the unique aspects of liver disease presentation and management in the elderly.
To discuss the implications of an aging population on the future burden of liver disease.
To highlight specific considerations for treating conditions like chronic hepatitis C and autoimmune hepatitis in older patients.

Main Methods:

Literature review of age-related liver disease considerations.
Analysis of clinical course and management differences in elderly versus younger patients.
Discussion of therapeutic approaches for common liver diseases in older adults.

Main Results:

Elderly patients with chronic hepatitis C may be candidates for antiviral treatment (pegylated interferon plus ribavirin), despite increased side effect risks.
Autoimmune hepatitis should be suspected in older individuals presenting with acute liver injury, jaundice, and hypergammaglobulinemia.
An increasing incidence of end-stage liver disease, decompensated cirrhosis, and hepatocellular carcinoma is anticipated in the aging population.

Conclusions:

Liver disease management in the elderly requires careful consideration of age-specific factors and potential treatment complications.
Early diagnosis and tailored immunosuppressive therapy are crucial for autoimmune hepatitis in older adults.
Healthcare systems must prepare for a growing number of elderly patients with advanced liver disease and related complications.